RxDoctor Payments Data

Kirsten Donner, PA

Physician Assistant · Wausau, WINPI 1518349505

Payments from drug & device makers

$1,915in general payments, 2019–2025

Across 68 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$533
  • AbbVie$199
  • Endo Pharmaceuticals Inc.$150
  • Medtronic$149
  • Sage Therapeutics, LLC$128
  • Sumitomo Pharma America, Inc.$99
  • plus $658 from 21 others

What the payments were for

  • Food & beverage$1,60784%
  • Education$30816%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,915 in reported general payments places this provider in the 90th percentile of 2,804 physician assistant providers in Wisconsin.

See all physician assistant providers in Wisconsin

Medicare billing

Part B allowed, 2024
$23,908
Medicare patients
187
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron261$135,311
GemtesaVibegron122$76,551
Tamsulosin Hcl662$11,933
Fosfomycin Tromethamine40$11,423
Methenamine Hippurate123$10,892
Trospium Chloride ErTrospium Chloride35$8,044
Solifenacin Succinate85$5,499
Potassium Citrate ErPotassium Citrate27$5,221
Estradiol65$4,983
Trospium Chloride68$3,655
Finasteride237$3,416
Desmopressin Acetate29$2,908
Oxybutynin Chloride ErOxybutynin Chloride104$2,854
Cephalexin66$987
Testosterone Cypionate44$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$533$135,311261 claims
Sumitomo Pharma America, Inc.Gemtesa$99$76,551122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,804 physician assistant providers in Wisconsin.

Other physician assistant in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →